Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund, Sweden.
Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden.
Cytometry B Clin Cytom. 2020 Sep;98(5):399-411. doi: 10.1002/cyto.b.21931. Epub 2020 Jun 16.
Accumulating data support the role of flow cytometry (FCM) in diagnostic work-up of myelodysplastic syndromes (MDS). Changes in erythropoiesis are less documented than in granulopoiesis. However, most studies were performed on bone marrow samples (BMSs) after red blood cell lysis. We have established a FCM protocol for erythropoiesis, following a no-lysis approach and live gate acquisition of nucleated cells using DNA dye DRAQ5.
The ERY tube consisted of CD36, CD71, CD105, CD117, CD13, and CD45. Comparison with cytomorphological differential counts was carried out in a learning cohort of 80 BMS. To detect aberrations, we analyzed 208 BMS from 135 patients and five normal donors, divided into three cohorts: MDS (n = 68), nonclonal cytopenia (n = 43), and normal controls (n = 29). Radar plot (RP) was created for an overview of normal and aberrant patterns.
The proportion of erythropoiesis in the ERY tube showed better agreement with the cytomorphology, compared to FCM panels on lysed BMS. We confirmed that aberrations in coefficient of variation (CV) of CD36 fluorescence intensity (p < .001), mean fluorescence intensity of CD36 (p = .012), and CV of CD105 (p < .001) can distinguish between MDS and nonclonal cytopenia. RP facilitated evaluation of erythropoietic maturation patterns and aberrant patterns were identified in 85% of MDS patients.
This study provides evidence that a no-lysis approach and RP analysis allow a more reliable evaluation of erythropoiesis and erythroid dysplasia, supporting the integration of FCM erythroid panels in the standard work-up of MDS.
流式细胞术(FCM)在骨髓增生异常综合征(MDS)的诊断中具有重要作用,越来越多的数据支持这一观点。与粒系生成相比,红系生成的变化记录较少。然而,大多数研究都是在红细胞裂解后对骨髓样本(BMS)进行的。我们建立了一种不裂解方法的 FCM 红细胞生成方案,并使用 DNA 染料 DRAQ5 对有核细胞进行活门采集。
ERY 管包含 CD36、CD71、CD105、CD117、CD13 和 CD45。在 80 例 BMS 的学习队列中进行了与细胞形态学差异计数的比较。为了检测异常,我们分析了来自 135 名患者和 5 名正常供体的 208 例 BMS,分为三组:MDS(n=68)、非克隆性血细胞减少(n=43)和正常对照组(n=29)。创建雷达图(RP)以概述正常和异常模式。
与裂解 BMS 的 FCM 面板相比,ERY 管中红细胞生成的比例与细胞形态学的一致性更好。我们证实,变异系数(CV)的 CD36 荧光强度(p<.001)、CD36 的平均荧光强度(p=.012)和 CD105 的 CV(p<.001)异常可区分 MDS 和非克隆性血细胞减少症。RP 便于评估红细胞生成成熟模式,并在 85%的 MDS 患者中发现异常模式。
本研究提供的证据表明,不裂解方法和 RP 分析可以更可靠地评估红细胞生成和红细胞发育不良,支持在 MDS 的标准检测中整合 FCM 红细胞面板。